Bluebird Bio reported $295.96M in Assets for its fiscal quarter ending in March of 2025.



Assets Change Date
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 96.05B 409M Sep/2026
Arrowhead Research USD 1.74B 373.76M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Tectonic Therapeutic USD 237.03M 9.54M Jun/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026